Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12062280 | 0.89 | KEAP1 (0.38) | KEAP1SMN1; SMN2CYP2D6ALOX15CYP1A2 | |
| SCHEMBL3318265 | 0.88 | ALOX15 (0.50) | CYP2D6ALOX15CYP1A2GNAI3GNAO1 | |
| SCHEMBL12062271 | 0.83 | GNAI3 (0.36) | KEAP1SMN1; SMN2CYP2D6ALOX15CYP1A2 | |
| SCHEMBL13602676 | 0.82 | CYP1A2 (0.47) | CYP2D6ALOX15CYP1A2GNAI3GNAO1 | |
| SCHEMBL17282197 | 0.82 | CYP1A2 (0.50) | SMN1; SMN2CYP2D6ALOX15CYP1A2SIGMAR1 | |
| SCHEMBL14199998 | 0.82 | GNAO1 (0.48) | CYP2D6ALOX15CYP1A2GNAI3GNAO1 | |
| SCHEMBL2209216 | 0.80 | KEAP1 (0.45) | KEAP1SMN1; SMN2CYP2D6ALOX15GNAI3 | |
| SCHEMBL19959037 | 0.80 | CYP1A2 (0.45) | CYP2D6ALOX15CYP1A2GNAI3GNAO1 | |
| SCHEMBL9038080 | 0.80 | CYP1A2 (0.45) | SMN1; SMN2CYP2D6ALOX15CYP1A2GNAI3 | |
| SCHEMBL26748937 | 0.80 | GNAO1 (0.56) | CYP2D6ALOX15CYP1A2GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-10654828-B2 | Indole derivatives and uses thereof | NOVARTIS AG (CH) | 2020-05-19 | — | — | US | disclosed |
| US-20190055219-A1 | INDOLE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-02-21 | — | — | US | disclosed |
| EP-1202738-A4 | DIHYDROPYRAZINE DERIVATIVES AS NPY ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-1202738-A1 | DIHYDROPYRAZINE DERIVATIVES AS NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6177429-B1 | SELECTIVE NEUROPEPTIDE Y (NPY) RECEPTOR ANTAGONISTS FOR PROMOTING WEIGHT LOSS AND TREATMENT OF EATING DISORDERS; ANOREXIGENIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2001-01-23 | — | — | US | disclosed |
| WO-2000078319-A1 | DIHYDROPYRAZINE DERIVATIVES AS NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055219-A1 | INDOLE DERIVATIVES AND USES THEREOF | MYLK2, MYOF, MUSK | KEAP1 1112/4885SMN1; SMN2 29/4885CYP2D6 4684/4885 |
| US-10654828-B2 | Indole derivatives and uses thereof | MYLK2, MYOF, MUSK | KEAP1 1112/4885SMN1; SMN2 29/4885CYP2D6 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.